Vertex Pharmaceuticals Incorporated
521.12USD
-7.7800 (-1.47%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-2.35▼ | $4.95 | 5 | 7 |
| Next quarter | $4.61▼ | $5.03 | 3 | 8 |
| Current year | $15.9▼ | $19.15 | 5 | 7 |
| Next year | $20.23▼ | $21.47 | 8 | 5 |
Beat in 2 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $4.75 | $4.73 | -0.02 (-0.3%) |
| 2026-03-31 | $4.31 | $4.47 | +0.16 (+3.8%) |
| 2025-12-31 | $5.15 | $5.03 | -0.12 (-2.3%) |
| 2025-09-30 | $4.58 | $4.8 | +0.22 (+4.9%) |
552 ratings from 47 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Truist Securities | Maintained | Buy | $560 $565 | Aug 5, 2026 |
| Barclays | Maintained | Overweight | $615 $617 | Aug 5, 2026 |
| TD Cowen | Maintained | Buy | $525 $550 | Aug 4, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $590 $595 | Aug 4, 2026 |
| Canaccord Genuity | Maintained | Hold | $436 $442 | Aug 4, 2026 |
| UBS | Maintained | Buy | $545 $585 | Jul 13, 2026 |
| Truist Securities | Maintained | Buy | $542 $560 | Jul 13, 2026 |
| RBC Capital | Maintained | Outperform | $543 $570 | Jul 7, 2026 |
| Baird | Maintained | Underperform | $330 $350 | Jul 7, 2026 |
| Barclays | Maintained | Overweight | $607 $615 | May 6, 2026 |
| Canaccord Genuity | Maintained | Hold | $437 $436 | May 5, 2026 |
| Morgan Stanley | Maintained | Overweight | $612 $616 | May 5, 2026 |
| Bernstein | Maintained | Outperform | $577 $572 | May 5, 2026 |
| RBC Capital | Maintained | Outperform | $541 $543 | May 5, 2026 |
| Canaccord Genuity | Maintained | Hold | $441 $437 | Apr 30, 2026 |
| Morgan Stanley | Maintained | Overweight | $596 $612 | Apr 10, 2026 |
| Maxim Group | Upgraded from Hold | Buy | $575 | Mar 18, 2026 |
| Truist Securities | Maintained | Buy | $490 $525 | Mar 11, 2026 |
| Morgan Stanley | Maintained | Overweight | $570 $596 | Mar 10, 2026 |
| B of A Securities | Maintained | Buy | $571 $598 | Mar 10, 2026 |
| Citigroup | Maintained | Buy | $575 $585 | Mar 10, 2026 |
| Oppenheimer | Maintained | Outperform | $540 $600 | Mar 10, 2026 |
| Jefferies | Initiated | Buy | $580 | Mar 10, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $591 $641 | Mar 10, 2026 |
| Canaccord Genuity | Maintained | Hold | $411 $441 | Feb 17, 2026 |
150 filings from 23 insiders · 9 buy / 18 sell over 6m
Officers and directors of VRTX, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Ambrose KristenOfficer, SVP & Chief Accounting Officer | Grant | 5.0k | — | — | Aug 28, 2026 |
| SACHS BRUCE IDirector | Gift | 6.0k | — | — | Aug 27, 2026 |
| TATSIS OURANIAOfficer | Grant | 8.3k | — | — | Jul 21, 2026 |
| SACHDEV AMITOfficer | Grant | 8.3k | — | — | Jul 21, 2026 |
| MCKECHNIE DUNCAN J.Officer | Sell | 1.5k | $519.00 | $800k | Jul 2, 2026 |
| TATSIS OURANIAOfficer | Sell | 1.5k | $524.99 | $787k | Jul 2, 2026 |
| LIU JOYOfficer | Sell | 828 | $502.71 | $416k | Jul 1, 2026 |
| BOZIC CARMENOfficer | Sell | 596 | $482.50 | $288k | Jun 26, 2026 |
| BOZIC CARMENOfficer | Sell | 1.0k | $462.17 | $471k | Jun 18, 2026 |
| BOZIC CARMENOfficer | Sell | 4.1k | $450.00 | $1.83M | Jun 15, 2026 |
| BOZIC CARMENOfficer | Sell | 1.7k | $450.00 | $785k | Jun 5, 2026 |
| LIU JOYOfficer | Sell | 828 | $439.91 | $364k | Jun 1, 2026 |
| BOZIC CARMENOfficer | Sell | 2.0k | $450.00 | $888k | May 29, 2026 |
| BUNNAGE MARK E.Officer | Sell | 33 | $453.45 | $15k | May 15, 2026 |
| BOZIC CARMENOfficer | Sell | 1.4k | $453.45 | $614k | May 15, 2026 |
| BOZIC CARMENOfficer | Sell | 7.0k | $450.00 | $3.14M | May 12, 2026 |
| BHATIA SANGEETA NDirector | Sell | 318 | $423.73 | $135k | May 4, 2026 |
| LIU JOYOfficer | Sell | 1.1k | $425.02 | $469k | May 1, 2026 |
| THORNBERRY NANCY A.Director | Grant | 472 | — | — | May 1, 2026 |
| BHATIA SANGEETA NDirector | Grant | 943 | — | — | May 1, 2026 |
No analyst notes on VRTX yet.
Analyst Ratings
26 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 5 | 19 | 4 | 1 | 1 | Buy2.13 |
| 1 mo ago | 4 | 19 | 4 | 1 | 1 | Buy2.17 |
| 2 mo ago | 4 | 19 | 4 | 1 | 1 | Buy2.17 |
| 3 mo ago | 6 | 21 | 4 | 1 | 1 | Buy2.09 |